Abandoned trial sought to save Insulin-Making cells in type 1 diabetes
NCT ID NCT02586831
First seen Jan 16, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study planned to test a combination of four drugs (ATG, low-dose IL-2, adalimumab, and exenatide) in people aged 18-35 newly diagnosed with type 1 diabetes. The goal was to see if the treatment could help the body keep making its own insulin and improve immune regulation. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.